Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

50.91USD
17 Nov 2017
Change (% chg)

$0.41 (+0.81%)
Prev Close
$50.50
Open
$50.63
Day's High
$51.05
Day's Low
$50.52
Volume
1,118,406
Avg. Vol
1,919,317
52-wk High
$51.05
52-wk Low
$30.89

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $99,809.84
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.47
Yield (%): 2.25

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Novo Nordisk CEO says still looking for biopharma bolt-on acquisitions

Nov 1 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN MADE FOLLOWING COMMENTS ON AN ANALYST CALL:

Nov 01 2017

Drugmaker Novo Nordisk warns of U.S. legislation, cautious on 2018

COPENHAGEN Drugmaker Novo Nordisk forecast only muted growth in 2018 and warned that draft legislation in some U.S. states to make pricing more transparent could impact business in its largest market.

Nov 01 2017

UPDATE 2-Drugmaker Novo Nordisk warns of U.S. legislation, cautious on 2018

* Shares fall on cautious 2018 outlook (Writes through with CEO comments)

Nov 01 2017

Drugmaker Novo Nordisk warns U.S. legislation could make business difficult

COPENHAGEN Drugmaker Novo Nordisk said on Wednesday that new legislation being prepared in some U.S. states to improve pricing transparency could potentially impact business in its key market.

Nov 01 2017

Drugmaker Novo Nordisk warns U.S. legislation could make business difficult

COPENHAGEN, Nov 1 Drugmaker Novo Nordisk said on Wednesday that new legislation being prepared in some U.S. states to improve pricing transparency could potentially impact business in its key market.

Nov 01 2017

Diabetes drugmaker Novo Nordisk expects low to mid single-digit growth in 2018​

COPENHAGEN, Nov 1 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, posted third-quarter operating profit slightly above forecasts on Wednesday, and said it expected low to mid single-digit sales and operating profit growth next year.

Nov 01 2017

BRIEF-Novo Nordisk Q3 EBIT DKK 12.04‍​ bln, slightly higher than expected

* Q3 SALES ‍​26.6 BILLION DKK VERSUS 27.24 BILLION DKK SEEN IN REUTERS POLL

Nov 01 2017

Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

WASHINGTON/COPENHAGEN Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug.

Oct 19 2017

Reuters Business News Schedule at 0830 GMT/430AM ET

China's Q3 economic growth slows as expected, property measures bite

Oct 19 2017

UPDATE 3-Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

WASHINGTON/COPENHAGEN, Oct 19 Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug.

Oct 19 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €75.43 -0.54
Eli Lilly and Co (LLY.N) $82.89 -0.55

Earnings vs. Estimates